Sanofi SA will cut the cost of the company’s insulin products to $99 per month for uninsured patients and others who pay cash for the medicine in the United States, as the French drugmaker contends with intense criticism over the high price of the life-sustaining diabetes medication.
Prices, profits and promotional spend are closely linked. Reduce prices and promotion will plummet. But wait, the Republicans are in control. Accordingly, pharma, its marketing partners and even Wall Street often rest easy, especially when Republicans control Congress and the White House.
Sanofi SA and Regeneron Pharmaceuticals Inc. will slash the U.S. list price of the companies’ potent but expensive cholesterol fighter Praluent by 60 percent.
The cost of insulin prevents many people with diabetes from taking it as directed, a small survey suggests.
Immunotherapy – reprogramming the immune system to attack cancer cells – is a rapidly growing and promising field in cancer research and treatment.
PTC Therapeutics announced interim data from part 1 of the company’s open-label clinical trials of risdiplam (RG7916) for Type 1, 2 and 3 spinal muscular atrophy (SMA).
Gilead Sciences Inc. plans to launch generic versions of the company’s hepatitis C drugs in the United States, at a time when regulators are looking to lower healthcare costs.
Shares of Israeli drugmaker Teva Pharmaceutical Industries rose more than 5 percent after the U.S. Food and Drug Administration approved the company’s new migraine treatment.
Novartis received European approval for Kymriah, the Swiss drugmaker’s gene-modifying therapy for blood cancer.
U.S. Health and Human Services Secretary Alex Azar said it was within his agency’s power to eliminate rebates on prescription drug purchases, a key element of the Trump administration’s plan to lower prescription medicine costs.
U.S. health regulators approved Amicus Therapeutics’ Galafold as the first oral therapy to treat Fabry disease, a rare and sometimes fatal condition.